EQUITY SECURITIES PORTFOLIO INVESTMENT (Tables)

9 Months Ended

Sep. 30, 2024

Investments, Debt and Equity Securities [Abstract]

Unrealized Gain (Loss) on Investments

Equity securities for the periods presented were comprised of the following:

Security Type	Cost		Gross Unrealized Gain		Gross Unrealized Loss		Fair Value
	(In thousands)
September 30, 2024:
Equity securities - other common stock	$	19,971	$	5	$	(5,876)	$	14,100
Total	$	19,971	$	5	$	(5,876)	$	14,100
December 31, 2023:
Equity securities - Life Sciences Portfolio	$	28,498	$	28,600	$	(20)	$	57,078
Equity securities - other common stock	4,925		1,080		(15)		5,990
Total	$	33,423	$	29,680	$	(35)	$	63,068

The following unrealized and realized gains or losses from our investment in the Life Sciences Portfolio are recorded in the change in fair value of equity securities and gain or loss on sale of equity securities, respectively, in the consolidated statements of operations:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
	(In thousands)
Change in fair value of equity securities of public    companies	$	—	$	8,187	$	(28,581)	$	7,677
Gain on sale of equity securities of public    companies	—		—		28,581		—
Net realized and unrealized gain	$	—	$	8,187	$	—	$	7,677